Losartan Potassium Tablet, Film Coated
Product Images NDC 62332-029

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 62332-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Losartan Fig1)

A line graph comparing the percentage of patients with the primary endpoint over 66 months for Atenolol and Losartan Potassium tablets. The graph shows a lower percentage for Losartan Potassium, indicating a 13% adjusted risk reduction with a significance of p=0.021.*

FDA Label Image

Figure 2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of up to 66 months between Atenolol and Losartan Potassium Tablets. The graph shows lower stroke rates for Losartan Potassium, indicating an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan potassium tablets and Atenolol across categories by event rate percentage and hazard ratio with 95% confidence intervals. It shows primary composite and stroke (fatal/non-fatal) outcomes among different subgroups, including age, gender, race, ischemic heart disease presence, diabetes status, and history of cardiovascular disease. The plot uses hazard ratios to indicate whether outcomes favor Losartan potassium tablets or Atenolol.*

FDA Label Image

Figure 4 (Losartan Fig4)

A line graph depicting the percentage of patients with an event over 48 months, comparing Losartan Potassium Tablets to a placebo. The solid line represents Losartan Potassium Tablets, and the dashed line represents placebo. The graph shows a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartan mg100

Label for Losartan Potassium Tablets, USP 100 mg film coated tablets. The label indicates the product is for prescription use and comes in a package of 30 tablets. Manufactured by Alembic Pharmaceuticals Limited, India, and for Alembic Pharmaceuticals, Inc., USA. The label includes storage instructions and dosage information references.*

FDA Label Image

Losartan mg25

Losartan Potassium Tablets, USP 25 mg film-coated tablets in a package containing 30 tablets. The label includes dosage information, storage instructions, and manufacturer details: Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, Inc., USA. The label is marked Rx only and contains a barcode and lot number area.*

FDA Label Image

Losartan mg50

Label for Losartan Potassium Tablets, USP 50 mg oral film-coated tablets by Alembic Pharmaceuticals Inc. The label includes NDC 62332-028-30, directions for storage, dosage instructions referencing the accompanying circular, and packaging information indicating 30 tablets per container. It notes the manufacturer locations in India and the USA.*

FDA Label Image

Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium showing its molecular components and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.